There has been a decision not to pursue the TGA provisional...

There has been a decision not to pursue the TGA provisional approval, so I forgave those comments. Clearly this decision was made by the team and not Paul, for whatever reason. It appears, they have taken a different direction since this was filmed.

My take is, the experts/consultants feel the juice has the game to produce the consistent safe data, hence the 008 study and the progress of MPS phase 2 studies to read out and then do a deal with.

This allows the big pharma to scoop up an impressive package with multiple options to commercialisation with the data to roll out as required. I suspect this thing won’t get too far into its phase 3 trial before the deals are getting done.

It’s positioned nicely. Paul’s TGA comments haven’t aged well but through the lens of courting big pharma, perhaps we have gone down the scenic route for a reason.